AXL: Advanced Opioid Use Disorder X-waiver Team Learning Collaborative Medication Assisted Treatment in Vermont Correctional Facilities

Dartmouth Health Continuing Education for Professionals Home, AXL: Advanced Opioid Use Disorder X-waiver Team Learning Collaborative Medication Assisted Treatment in Vermont Correctional Facilities, 9/1/2021 12:00:00 PM - 9/1/2024 1:00:00 PM,

Content includes:

• Transitions of MAT between DOC & Hubs/Spokes
• Impact of care setting on medications & formulations 
• Service coordination between Corrections & community providers

VT DOC MAT Program

• Foundational Legislation
• Program Clinical Guidelines
• Medication-first, Recovery-oriented Care
• Psychosocial Support Structures
• Care Coordination:  planned & rapid
• Impact of COVID-19 on DOC MAT Program & Transitions of Care

Presenter
Sharif Nankoe, MD, MPH

Dr. Sharif Nankoe is the Medical Director for the Vermont Department of Corrections Medication-Assisted Treatment Program.  He is board certified in addiction medicine.  He previously served as the Medical Director for two of Vermont’s Hubs and two Spokes.

Annie Ramniceanu, LADC, LMHC

Annie Ramniceanu has worked in the field of community-based integrated mental health and substance use disorder treatment with the criminal justice population for over 20 years. Her roles have included serving as the Clinical Director of a youth and young adult-based nonprofit, Adjunct Professor at the University of Vermont School of Education, and Associate Professor at the University of Vermont Medical College.  She was also the Chair of the Vermont Alcohol and Drug Certification Board and is currently appointed as a special advisor to the Vermont Secretary of State Office of Professional Regulation. Annie transitioned to working in state government in 2014 when she was appointed as the first Pretrial Services Director in Vermont by Governor Shumlin. In 2016, Pretrial Services was transitioned to the Attorney General’s office and she was reappointed to serve the Commissioner of Corrections.  As such, she acts the Addiction and Mental Health Systems Director.

Learning Outcome
Participants will be able to identify at least three evidence-based strategies that are designed to enhance the clinical team-based care of patients with substance or opioid use disorders treatment. 

Disclosure
The activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported NO financial relationship(s)* with ineligible companies**.

* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).

** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Bibliographic Material

1. Boys A, Farrell M, Bebbington P, Brugha T, Coid J, Jenkins R, Lewis G, Marsden J, Meltzer H, Singleton N, Taylor C.   Drug Use and Initiation in Prison:  Results from a National Prison Survey in England and Wales. Addiction 2002 Dec; 97(12): 1551-1560.
2. Bronson, J., Stroop, J., Zimmer, S., & Berzofsky, M. Drug Use, Dependence, and Abuse Among State Prisoners and Jail Inmates, 2007-2009.  Washington, DC: United States Department of Justice, Bureau of Justice Statistics, 2017.
3. Crotty K, Freedman K, Kampman KM. The American Society of Addiction Medicine (ASAM) National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. J. Addict Med. 2020 Mar/Apr; 14 supplement 1 2S.
4. Mace, S., Siegler, A. Wu, K., Latimore, A., Flynn, H. Medication-Assisted Treatment for Opioid Use Disorder in Jails and Prisons: A Planning and Implementation Toolkit. The National Council for Behavioral Health and Vital Strategies, January 2020.
5. National Center on Addiction and Substance Abuse at Columbia University.  Behind Bars II:  Substance Abuse and America’s Prison Population. 2010.
6. O’Hagan A, Hardwick R.  Behind Bars: The Truth about Drugs in Prisons. Forensic Res Criminol Int J 2017 Sept; 5(3): 00158.
7. Substance Abuse and Mental Health Services Administration (SAMHSA).  Use of Medication-Assisted Treatment for Opioid Use Disorder in Criminal Justice Settings, July 2019.
8. Vermont General Assembly. The Vermont Statutes Online Title 18: Health.  https://legislature.vermont.gov/statutes/title/18. Accessed May 25, 2021.
9. Vermont General Assembly. The Vermont Statutes Online, Title 28: Public Institutions And Corrections.  https://legislature.vermont.gov/statutes/title/28. Accessed May 25, 2021.
10. Substance Abuse and Mental Health Services Administration. SAMHSA’s Working Definition of Recovery.  https://store.samhsa.gov/sites/default/files/d7/priv/pep12-recdef.pdf. Accessed May 25, 2021.
11. US Bureau of Justice. Prisoners In 2006. 2006; https://www.bjs.gov/index.cfm?ty=pbdetail&iid=908. Accessed May 25, 2021.
12. US Bureau of Justice. Survey Of Inmates In Federal Correctional Facilities. 2004; https://www.bjs.gov/index.cfm?ty=dcdetail&iid=273. Accessed May 25, 2021.
13. US Bureau of Justice. Survey Of Inmates In Local Jails. 2002; https://www.bjs.gov/index.cfm?ty=dcdetail&iid=274. Accessed May 25, 2021.
14. Binswanger IA, Stern MF, Deyo RA, et al. Release from Prison — A High Risk of Death for Former Inmates. New England Journal of Medicine. 2007;356(2):157-165.
15. Knight K. TCU Drug Screen 5.  https://ibr.tcu.edu/wp-content/uploads/2017/09/TCU-Drug-Screen-5-v.Aug17.pdf. Accessed May 25, 2021.